Feature | December 28, 2012

American College of Cardiology Names Top Cardiovascular Stories of 2012

Top Cardiovascular Stories 2012 Software CT angiography Heart Valve Repair

December 28, 2012 — The past year in cardiology has continued to see progress and innovation in medicine. As the year comes to an end, the American College of Cardiology (ACC) identified some of the top cardiovascular stories of 2012.

Electronic applications moved into the doctor’s office. iPhone apps were introduced to generate electrocardiograms (ECGs), help diagnose atrial fibrillation or help patients quit smoking, while the ACC’s CardioSmart Explorer app was introduced to provide animated 3-D heart images to help cardiologists explain conditions to their patients.

The Choosing Wisely campaign got national attention. Medical societies, including the ACC, identified over-performed procedures that physicians and patients should discuss together. The campaign was meant to help open the discussion between patients and providers about the costs, risks and benefits of certain procedures.

The Affordable Care Act upheld. In June, the U.S. Supreme Court upheld the majority of the Affordable Care Act, with the court ruling the individual mandate was constitutional as a tax.

Bariatric surgery identified as tool for controlling diabetes in some. A new study, presented at ACC.12 in Chicago, found bariatric surgery with medical therapy was better than intensive medical therapy alone for controlling blood sugar in obese patients with type 2 diabetes.

The U.S Food and Drug Administration (FDA) expanded approved uses for transcatheter aortic valve replacement (TAVR). The FDA approved TAVR for high-risk patients. Previously, the FDA had approved the treatment for only inoperable patients.

Warfarin alternative approved. FDA approval was also given to rivaroxaban, a warfarin alternative, to treat pulmonary embolism and deep vein thrombosis.

Surgery identified as better than stents for some patients. Coronary artery bypass grafting (CABG) was shown in a study to be better than percutaneous coronary intervention (PCI) for treatment of patients with diabetes and multi-vessel coronary artery disease.

New cholesterol-lowering drug showed potential. PCSK9 inhibitors demonstrated success in significantly lowering LDL cholesterol. This development opens the door to promising new techniques and medicines for lowering cholesterol.

• Generic drugs impacted consumers. Generic forms of cholesterol-lowering statin Lipitor were marketed in 2012, and the patent for Plavix expired, leading to the FDA approval of generic alternatives.

For more information: www.cardiosource.org/ACC

Related Content

News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
ACC, American College of Cardiology, Google search, heart conditions, Health Knowledge Graphs
News | Information Technology| September 23, 2016
A Google search for heart conditions will now prominently display important questions patients should ask their doctor...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Lotus Edge Valve, CE mark, boston scientific, TAVR, TAVI

The Lotus Edge system in its deployed position. The Lotus valve expands outward as it is compressed and buckled in the deployment position. It also has a skirt to help eliminate paravalvular leaks.

News | Heart Valve Technology| September 19, 2016
September 19, 2016 — Boston Scientific received European CE mark approval for its Lotus Edge Valve System, the compan
Valtech Cardio, Cardioband Tricuspid, Cardioband Mitral, PCR London Valves 2016, study data
News | Heart Valve Technology| September 19, 2016
Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at...
Xeltis bioabsorbable aortic conduit, endogenous tissue restoration, ETR, preclinical data, ISACB 2016
News | Heart Valve Technology| September 09, 2016
Six-month preclinical data from trials of a Xeltis bioabsorbable aortic conduit were presented at the 2016 scientific...
Overlay Init